SynBioBeta Speaker
John DiLeo
MITRE
Dept Mngr, Life Sciences
John Dileo, Ph.D is a Senior Principal Biotechnologist and Manager of MITRE's Biotechnology and Life Science Department. In this role he oversees department efforts in the areas of biosafety, security and quality, c-WMD, medical countermeasures development, and human performance optimization and manages MITRE’s Biotechnology Horizon Strategy.As a researcher, Dr. Dileo has led experimental and theoretical efforts in molecular, systems, and synthetic biology focused on developing cell based sense and respond systems and tools for screening orders for synthetic DNA for the presence of biosecurity threats. As a subject matter expert and project lead, Dr. Dileo has provided support and oversight to numerous large US Government research and development programs at DARPA BTO, DTRA, JPEO-CBRND, DHS S&T, and other national security organizations. Specific efforts have focused on assessing the national security implications of emerging developments in biotechnology, preventing the proliferation and use of biological weapons, biomanufacturing, and working with USG program managers to develop and execute novel program/project concepts.Prior to joining MITRE, Dr. Dileo was a research fellow in the Department of Urology at Pittsburgh Cancer Institute. There his research focused on developing gene based immunotherapies for cervical and prostate cancer and novel gene delivery methods. Dr. Dileo received his Ph.D. in Molecular Genetics & Biochemistry in 2001 from the University of Pittsburgh School of Medicine.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
John
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
